Polarean Imaging (POLX) Share Price, News & Analysis

Company Overview

Polarean is a revenue-generating medical imaging technology company revolutionizing pulmonary medicine through direct visualization of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimize lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarization system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com

Key Stats

• Today's Range: 0.06 to 0.13
• 50-Day Range: 0.08 to 0.08
• 52-Week Range: 0.06 to 1.60
• Volume: 28.96 million shs
• Average Volume: 7.19 million shs
• Market Capitalization: £965.63 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: LON:POLX
• CIK: N/A
• Web: www.polarean.com
• Phone: 919 206 7900
• Fax: N/A
• Employees: 28
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£69.44 million
• Net Margins: -276.38%
• Pretax Margin: N/A
• Return on Equity: -65.39%
• Return on Assets: -32.28%

Debt

• Debt-to-Equity Ratio: 4.15
• Current Ratio: 4.64
• Quick Ratio: 9.80

Sales & Book Value

• Annual Sales: £2.56 million
• Price / Sales: 0.38
• Cash Flow: GBX 0.02 per share
• Price / Cash Flow: 4.93
• Book Value: GBX 3.30 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 1,207,033,000
• Free Float: N/A
• Market Cap: £965.63 thousand
• Optionable: Not Optionable
• Beta: 0.38